synthetic long peptide neoantigen vaccine

Synthetic long peptide (SLP) neoantigen vaccines are a class of personalized cancer immunotherapies designed to stimulate a patient's immune system against tumor-specific mutations. These vaccines consist of synthetic peptides, typically 25–30 amino acids in length, that encompass neoantigens identified through genomic sequencing of a patient's tumor. Unlike short peptides, SLPs require processing by professional antigen-presenting cells (APCs), which allows for the presentation of both MHC class I and class II epitopes, thereby activating both CD8+ cytotoxic T cells and CD4+ helper T cells. This dual activation is critical for generating robust and sustained anti-tumor immunity. These vaccines are often administered with adjuvants like poly-ICLC to enhance the innate immune response and are being investigated across various solid tumors, including melanoma, glioblastoma, and pancreatic cancer.

Other names

SLP neoantigen vaccinepersonalized peptide neoantigen vaccinesynthetic long peptide vaccineneoantigen-based synthetic long peptide vaccine